Access cutting-edge cardiovascular disease treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access cardiovascular disease specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cardiovascular disease treatment provided free
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the
Sponsor: AstraZeneca
Check if you qualify for this cardiovascular disease clinical trial in Birmingham, AL
If you're searching for cardiovascular disease treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cardiovascular disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.